You probably know someone who sleeps with a CPAP machine, or who tried one for a few weeks and quietly stowed it in a closet.
The mask, the hose, the hum. For a lot of people, it just never fits into real life.
Two large phase 3 trials have now shown that a once-nightly pill reduced the breathing interruptions of obstructive sleep apnea by around 44 to 47 percent.
The results were published in May 2026 in the American Journal of Respiratory and Critical Care Medicine.
Also read: How cottage cheese can affect your blood sugar
The drug, called AD109, is made by Apnimed. If the Food and Drug Administration approves it, it would be the first daily oral medicine for the condition.
How the pill is designed to work
Obstructive sleep apnea happens when the muscles around the upper airway relax too much during sleep.
The airway narrows or briefly closes, and breathing stops for a few seconds at a time.
This can happen hundreds of times a night, jolting the body awake and starving the brain of oxygen.
Also read: Giving your child a smartphone may raise their eating disorder risk
AD109 is a fixed-dose combination of two older medicines, aroxybutynin and atomoxetine, taken as a single capsule at bedtime.
It is designed to keep the muscles that hold the upper airway open more active during sleep, so the airway is less likely to collapse in the first place.
What the two trials found
The two trials, called SynAIRgy and LunAIRo, enrolled more than 1,300 adults with obstructive sleep apnea at centers across the United States and Canada.
Participants were randomly assigned to AD109 or an identical placebo.
The main cohort was followed for 26 weeks, with LunAIRo continuing to a full year.
The researchers tracked the apnea-hypopnea index, the standard measure of how many times breathing stops or becomes very shallow per hour of sleep.
After 26 weeks, people on AD109 saw their apnea-hypopnea index fall by about 44 percent in SynAIRgy.
In LunAIRo, the drop was close to 47 percent. In the placebo groups, improvements were much smaller.
Also read: Eating less ultra-processed food could help with depression
By the one-year mark in LunAIRo, about 22 percent of people on the pill had reached what doctors call full disease control, fewer than five breathing events per hour.
Oxygen levels during the night also improved on the drug.
CPAP machines, the current standard treatment, push air through a mask to hold the airway open.
When worn every night they can bring breathing events almost to zero. But long-term use remains a well-known problem, and many people stop within the first year.
Also read: Shingles vaccine may also protect your heart, major study finds
AD109 does not clear sleep apnea the way CPAP can when it is used correctly.
The reduction in events is partial, and plenty of patients still have moderate or severe disease at the end of the trials.
The appeal is simply that a pill is easier to actually take.
Side effects and the FDA timeline
The pill was not without downsides. The most common side effects in the drug group were dry mouth, insomnia and nausea. Serious adverse events were rare.
But about one in five people on AD109 stopped treatment because of side effects, compared with roughly one in thirty on placebo.
That gap is substantial, and reviewers at the Food and Drug Administration are expected to weigh it carefully.
The agency accepted Apnimed's new drug application in July 2026, according to a company statement reported by NeurologyLive.
The decision date has been set for February 28, 2027.
If you snore loudly, wake up gasping or feel exhausted after a full night in bed, those can be signs of obstructive sleep apnea.
A doctor can refer you for a sleep study to confirm or rule it out, and that is the step to take before any new treatment, pill or otherwise, becomes relevant for you.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.